Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
OwnerRobert L. Bratzler, Deanna M. Peterseninventors
Life of this patent
Estimating the term…
Abstract
The invention involves administration of an immunostimulatory nucleic acid in combination with a cancer medicament for the treatment or prevention of cancer in subjects. The combination of drugs are administered in synergistic amounts or in various dosages or at various time schedules. The invention also relates to kits and compositions concerning the combination of drugs.
Claims25
A method for treating a subject having, or at risk of developing, a cancer, comprising:
- administering to a subject in need of such treatment a poly-G nucleic acid and a cancer medicament in an effective amount to treat the cancer or to reduce the risk of developing the cancer,
- wherein the poly-G nucleic acid is not conjugated to the cancer medicament.
3-5. (canceled)
(canceled)
A method for treating a subject having or at risk of developing a cancer, comprising:
- administering to a subject in need of such treatment, an immunostimulatory nucleic acid having a modified backbone and a cancer medicament selected from the group consisting of an immunotherapeutic agent, a cancer vaccine and a hormone therapy,
- wherein the immunostimulatory nucleic acid is free of a CpG motif, and a T-rich motif.
(canceled)
21-30. (canceled)
A method for treating a subject having or at risk of developing cancer, comprising
- administering to a subject in need of such treatment an immunostimulatory nucleic acid selected from the group consisting of a CpG nucleic acid and a non-CpG nucleic acid, and a cancer medicament that is a hormone therapy.
(canceled)
Dependencies are inferred from the claim text.